TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04267939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Elimusertib will be administered in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Elimusertib will be administered in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Elimusertib will be administered in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Elimusertib will be administered in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Elimusertib will be administered in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Elimusertib will be administered in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered in 28-day cycles.
Study: NCT01535638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 207127
Description: Medium dose film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 207127
Description: Medium dose film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 207127
Description: Medium dose film-coated tablet
Study: NCT01222767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalypsis
Description: Zalypsis is provided as a lyophilized powder for concentrate for solution for infusion in a strength of 2.5 mg/vial.
Study: NCT03700424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trehalose
Description: Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products.~In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: A solution of 0.90% w/v of sodium chloride (NaCl) in water
Study: NCT00609089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRAFT-T
Description: The Community Reinforcement and Family Training for Treatment Retention and HIV Risk Reduction treatment (CRAFT-T) was be developed in phase 1 and 2 of the current study and consists of twelve manual-guided weekly one-hour individual sessions for the concerned significant other and 2 one hour sessions for the identified patient. The intervention also allows for up to two additional sessions (total of 14 visits) to help arrange re-entry into substance abuse treatment when needed. The identified patient receives this intervention in addition to the usual services at the drug treatment program (Maryhaven).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual will be the normal course of treatment for concerned significant others (CSOs) in the outpatient department.
Study: NCT02769689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab (NTZ)
Description: Patients with MS receiving NTZ for at least 18 months and without any disease activity during the previous year will be eligible. Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fingolimob (FTY)
Description: Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.
Study: NCT04628754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and protein
Description: Home based exercise regime and dietary protein guidance
Study: NCT04401345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.2 MG/ML
Description: In this group, the patients will receive glycopyrrolate 0.2 mg in 1 ml
Study: NCT04653688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The FeetMe® Evaluation
Description: The FeetMe® Evaluation device is a medical device (class Im CE 0459) for ambulatory gait analysis, consisting of a pair of connected insoles and an Android mobile application.
Study: NCT05156697

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsinoids + Exercise
Description: 60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + supplementation with 12 mg of dihydrocapsiate (7 min before starting the aerobic exercise)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Exercise
Description: 60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + placebo pills (7 min before starting the aerobic exercise)
Study: NCT01866839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graft Manipulation (CD34+ Selection)
Study: NCT01721304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive Conjoint Analysis
Description: Computerized survey to elicit patient preferences
Study: NCT01171755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine TS-1
Description: Gemcitabine (1,000mg/m2) will be administered on days 1 and 8 at every 3 weeks TS-1 will be administered orally according to body surface area (BSA) as follows : BSA\<1.25 M2, 80 mg/day; 1.25 M2≤BSA\<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
Study: NCT00535405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Description: Atorvastatin 10 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/simvastatin 20 mg
Description: Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Description: Atorvastatin 20 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
Study: NCT01465984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: paracetamol , 1 gram Iv infusion Morphine Sulfate0.1 Mg/Kg Iv
Study: NCT04653688

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: The FeetMe® Evaluation
Description: The FeetMe® Evaluation device is a medical device (class Im CE 0459) for ambulatory gait analysis, consisting of a pair of connected insoles and an Android mobile application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the PKG® Watch,
Description: The PKG® provides continuous, objective, ambulatory assessment of the treatable and disabling symptoms of Parkinson's disease including tremor, bradykinesia and dyskinesia. The PKG® system consists of a wrist-worn movement recording device known as the PKG® Watch,

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: * an anatomical 3D T1-weigthed gradient-echo sequence (1mm isotropic):~* anatomical registration~* automated segmentation~* volumetric~* texture analysis

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: MRI
Description: * an anatomical 3D T1-weigthed gradient-echo sequence (1mm isotropic):~* anatomical registration~* automated segmentation~* volumetric~* texture analysis

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DaTSCAN
Description: * quantify nigrostriatal dopaminergic depletion~* correlate its impact on the type and severity of gait disorders in Parkinson's disease.
Study: NCT04401345

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: In this group, the patients will receive 1 ml of 0.9% normal saline
Study: NCT01689545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual level
Description: Index participants will participate in standard HIV VCT supplemented with 2 posttest counseling sessions, followed by 2 post-test skill-building support groups for HIV positive IDUs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual level
Description: Index participants will participate in standard HIV VCT supplemented with 2 posttest counseling sessions, followed by 2 post-test skill-building support groups for HIV positive IDUs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structural level
Description: Community members will participate in 2 community-based HIV and IDU stigma videos combined with a series of visits with community outreach workers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structural level
Description: Community members will participate in 2 community-based HIV and IDU stigma videos combined with a series of visits with community outreach workers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual level standard of care
Description: The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual level standard of care
Description: The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.
Study: NCT01249638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine:2 x 1250 mg/m2 day 1-14 followed by 1 week pause q day 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab: 7.5 mg/kg day 1 q day 21
Study: NCT01689545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structural level standard of care
Description: Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
Study: NCT01249638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine: 2 x 800mg/m2 day 1-14 followed by 1 week pause q day 21
Study: NCT01689545

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structural level standard of care
Description: Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
Study: NCT01249638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan: 200 mg/m2 day 1 , q day 21
Study: NCT03397992

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Changing dialysate temperature
Description: Patients had SLED with low dialysate temperature (around 35°C) compared with high dialysate temperature (around 37°C)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Changing dialysate temperature
Description: Patients had SLED with low dialysate temperature (around 35°C) compared with high dialysate temperature (around 37°C)
Study: NCT01637389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Safe Water Program
Description: The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Basic Safe Water Program receives: the community meeting; installation of a Mesita Azul; a six month technical guarantee; one safe-storage container; training of one household member in operation and basic maintenance of the technology; training of at least one local resident in repair and system maintenance; and follow up after four to six months of the installation date.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Safe Water Program
Description: The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Enhanced program complements the Basic version with: a water quality analysis and presentation of results to households at the community meeting; a six-month money back guarantee; the provision of two safe-storage containers to facilitate access to disinfected water at different locations within the household; training of two household members in operation and basic maintenance of the technology; an additional follow up visit about two weeks after the installation date.
Study: NCT02673567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125 - 1
Description: Subcutaneous administration Dose Regimen 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125 - 2
Description: Subcutaneous administration Dose Regimen 2
Study: NCT01465984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: paracetamol , 1 gram Iv infusion Morphine Sulfate0.1 Mg/Kg Iv
Study: NCT02673567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125 - 3
Description: Subcutaneous administration Dose Regimen 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT03701997

Intervention type: DEVICE
Intervention: EXCOR Pediatric
Description: Mechanical circulatory support using ventricular assist device
Study: NCT01249638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab: 7.5 mg/kg day 1, q day 21
Study: NCT00535405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/simvastatin 40 mg
Description: Ezetimibe 10 mg/simvastatin 40 mg and Placebo for atorvastatin once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Description: Atorvastatin 40 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
Study: NCT03909100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSculpting® System
Description: A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
Study: NCT04422392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: (IV, Q3W)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: (IV, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed or Nab-paclitaxel
Description: Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel (Squamous NSCLC) (IV, Q3W)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed or Nab-paclitaxel
Description: Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel (Squamous NSCLC) (IV, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: (IV, Q3W)
Study: NCT06506006

Intervention type: BIOLOGICAL
Intervention: Covid infection
Description: outcome with and without covid infection
Study: NCT01711359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally
Study: NCT00841750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Do not leave a chest tube in the pleural cavity.
Description: At the end of a VATS wedge resection, an air leak proof will take place and if no air leak is noted, the surgical incisions for thoracoscopy ports will be closed without leaving a chest tube inserted in the pleural cavity of the patient.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Do leave a chest tube in the pleural cavity.
Description: At the end of a VATS wedge resection, a chest tube will be inserted in the pleural cavity of the patient through the inferior surgical incision for thoracoscopy port; the rest of the incisions will be closed.
Study: NCT01530841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nocturnal ventilation
Description: Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.
Study: NCT01711359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib Placebo
Description: Baricitinib placebo administered orally once daily.
Study: NCT01530841

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal ventilation
Description: Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.
Study: NCT03448887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova
Description: Extended HD with theranova

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Online hemodiafiltration
Description: Online hemodiafiltration
Study: NCT01711359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX Placebo
Description: MTX placebo administered orally once weekly.
Study: NCT02289976

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: core decompression
Description: Drilling of the avascular necrosis of the talus by 10mm drill under x-ray control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: core decompression
Description: Drilling of the avascular necrosis of the talus by 10mm drill under x-ray control
Study: NCT04482387

Intervention type: DEVICE
Group type: OTHER
Intervention: DigiVis visual acuity app
Description: Self-testing of visual acuity app on two occasions
Study: NCT01366625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation with a catheter-based procedure (Symplicity® Catheter System)
Description: Disruption of the renal nerves with a catheter-based procedure.
Study: NCT00005957

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Breast Irradiation
Description: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Breast Radiation plus Regional Radiation
Description: Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.
Study: NCT02227823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Study: NCT02838615

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural steroid (dexamethasone) injection
Description: spinal injections performed in epidural space to relieve chronic low back pain or leg pain
Study: NCT00197730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multivitamins - vitamins B complex, C and E
Description: Age-appropriate dosages of vitamin C, vitamin E, thiamine, riboflavin, niacin, vitamin B6, folate, and vitamin B12 administered orally to children aged 6 weeks to 6 months, and two capsules per day for children aged older than 6 months for at least 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules administered orally once day orally to children aged 6 weeks to 6 months, and twice per day for children aged older than 6 months
Study: NCT04760912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium used for neuromuscular blokade during anesthesia and anesthesia without rocuronium

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia for surgery
Description: General anesthesia with standard anesthetic monitoring,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia for surgery
Description: General anesthesia with standard anesthetic monitoring,
Study: NCT01988545

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1,5 nmol/kg,GLP-1 sc injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1,5 nmol/kg,GLP-1 sc injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 1,5 nmol/kg,GLP-1 sc injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1,5 nmol/kg GLP-1 9-36amide, sc injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1,5 nmol/kg GLP-1 9-36amide, sc injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 1,5 nmol/kg GLP-1 9-36amide, sc injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-4 ;10 ug,sc injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-4 ;10 ug,sc injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline